Page 15 - Lupin
What are Lupin CEO Vinita Gupta's plans for growth in US & China?
In conversation with Business Standard's Sohini Das, Lupin CEO Vinita Gupta shared her company's growth plans in the US and in China. Let us listen in to the interview
 "What are Lupin CEO Vinita Gupta's plans for growth in US & China?")
TMS Ep104: Brands & politics, Vinita Gupta, markets, Central Vista
Why brands should stay away from politics? What are Lupin CEO's plans for growth in US & China? Can investors benefit from Brent crude rally? What is the Central Vista project? Find all answers here
 "TMS Ep104: Brands & politics, Vinita Gupta, markets, Central Vista")
Lupin slips 9% in two days, hits 52-week low on disappointing Q3 results
In the past six months, the stock has shed nearly 30 per cent, as compared to a 7 per cent rise in the S&P BSE Sensex.
 "Lupin slips 9% in two days, hits 52-week low on disappointing Q3 results")
We are working on developing a China pipeline: Lupin CEO Vinita Gupta
Lupin's CEO Vinita Gupta tells Sohini Das about the company's global plans
Lupin consolidated net profit up 24% at Rs 545 crore in Dec quarter
Drugmaker Lupin reported a 24.45 per cent rise in its consolidated net profit at Rs 545.5 crore for the third quarter ended December 31
Lupin slips 5%, nears 52-week low post December quarter results
The company reported lower-than-expected margins and net profit in December quarter due to one-time expenses related to residual metformin returns and provision for aged stock returns of Oseltamivir.
 "Lupin slips 5%, nears 52-week low post December quarter results")
Stocks to Watch: RIL, ITC, TCS, Titan, Cadila, Emami, Lupin, EIH, Tyre
BoI, Devyani Intl, Eveready, FSL, Mahindra Life, Paytm, REC, Siemens, Sintex, SPARC, Tata Steel, Thermax and Vijaya Diagnostics are some of the prominent companies to announce results today.
 "Stocks to Watch: RIL, ITC, TCS, Titan, Cadila, Emami, Lupin, EIH, Tyre")
Sensex snaps 3-day winning run, ends 770 pts down; Nifty tops 17,750
Among sectors, all the key indices ended in the red, led by the Nifty IT index (down 2 per cent) and the Nifty Realty index (down 1.7 per cent). Nifty Auto index was the only gainer, up 0.4 per cent.
 "Sensex snaps 3-day winning run, ends 770 pts down; Nifty tops 17,750")
Stocks to Watch: HP Adhesives, RBL Bank, Adani Trans, HUL, Lupin, CBI
HP Adhesives is likely to debut with a 20-25 per cent listing gain, as per indications from the GMP
Lupin receives tentative USFDA nod for generic Azilsartan Medoxomil tablets
The tentative approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) Azilsartan Medoxomil tablets is for strengths of 40 mg and 80 mg
US business rebound key to further upsides in Lupin, VAI may offer relief
Clearance for Goa unit is positive; near-term triggers are new launches and market share gains
Stocks to Watch: ITC, Lupin, ABFRL, Glenmark, NBFCs, Tata group stocks
The RBI on Tuesday introduced a prompt corrective action (PCA) framework for large non-banking financial companies (NBFCs)
 "Stocks to Watch: ITC, Lupin, ABFRL, Glenmark, NBFCs, Tata group stocks")
US FDA clears Lupin's Goa plant, paves way for new product approvals
Goa plant has an annual capacity of 6 billion units of tablets, capsules or oral suspension drugs. It accounts for 18-20% of firm's US revenue
Market wrap: Benchmarks end lower for a second day; Sensex slips 166 pts
NBFCs to come under the ambit of PCA framework from Oct 2022; Anand Rathi Wealth debuts at 9% premium; WPI-based inflation hits 12-year high of 14.2% in Nov
 "Market wrap: Benchmarks end lower for a second day; Sensex slips 166 pts")
Lupin receives inspection report from USFDA for Goa manufacturing facility
Homegrown pharma major Lupin Ltd on Tuesday said it has received the Establishment Inspection Report (EIR) from USFDA for its Goa manufacturing facility after an inspection in Sept 2021
Lupin surges 10% on good volumes after getting EIR from USFDA for Goa plant
Despite of today's gain, the stock has underperformed the market by falling 18 per cent in past six months, as compared to 10.5 per cent rally in the S&P BSE Sensex
Stocks to Watch: RIL, Lupin, SBI, Maruti, PowerGrid, Minda, BoM, Vedanta
Maruti Suzuki India (MSI) is currently analysing customer feedback to ascertain if the Jimny brand can be introduced in India
Lupin recalls 4,113 cartons of oral contraceptive medicine in US market
Homegrown drug maker Lupin is recalling 4,113 cartons of generic oral contraceptive tablets in the US, the world's largest market for medicines, due to manufacturing issues. As per the latest enforcement report issued by the US Food and Drug Administration (USFDA), Lupin's US-based unit is recalling 4,113 cartons of Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg). The affected lot has been produced at the company's Pithampur-based manufacturing facility in Madhya Pradesh and distributed in the US by Baltimore-based Lupin Pharmaceuticals, Inc. The company is recalling the lot due to it being Subpotent Drug, the US health regulator noted in the report. Lupin initiated the nationwide recall on November 19 this year, it added. The USFDA has classified both the recalls as class III. As per the US health regulator, a class III recall is initiated in a situation in which use of, or exposure to, a .
 "Lupin recalls 4,113 cartons of oral contraceptive medicine in US market")
Lupin to set up 100 diagnostic labs and 1,000 collection centres in 5 yrs
Announced foray into fragmented diagnostic business where organised chains have less than 20% share of overall business
Pharma major Lupin announces launch of its diagnostics business
Homegrown pharma major Lupin Ltd on Friday announced the launch of its diagnostics arm as part of its strategy to provide integrated healthcare in India.